Thursday 23 February 2012
BioTheranostics develops and provides innovative oncology tests to support targeted disease management.
CancerTYPE ID® is a molecular test that uses the differential expression of 92 genes to aid in the determination of tumor site of origin.
Breast Cancer IndexSM is a prognostic biomarker that provides quantitative assessment of the likelihood of distant recurrence in patients diagnosed with estrogen receptor-positive, lymph node-negative breast cancer.
PRÉCIS Precision Medicine includes biomarker profiles for non-small cell lung and colorectal cancer that detect clinically relevant tumor biomarkers.